|Secondary Protocol No.
||MT2005-25 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
||This phase II trial is studying how well a non-irradiation containing chemotherapy regimen followed by a double umbilical cord blood transplant works in treating infants with high-risk acute leukemia or myelodysplastic syndromes.
||Treatment includes non-irradiation containing myeloablative conditioning regimen and an umbilical cord blood transplant. After completion of study treatment, patients are followed periodically for at least 5 years.
||Giving chemotherapy, including busulfan, fludarabine, and melphalan, before a double umbilical cord blood stem cell transplant helps as treatment for infant leukemia.
||Patients diagnosed with acute myeloid leukemia , acute lymphoblastic leukemia or myelodysplastic syndrome (in complete remission).
|Applicable Disease Sites
||Acute Lymphocytic Leukemia (ALL)
Acute myeloid leukemia (AML)
Myelodysplastic syndromes (MDS)
||Blood and Marrow Transplant
||Masonic Cancer Center
||Patient must be no more than 2 years of age at the time of diagnosis. Patients with active infection at time of transplantation or history of HIV infection are not eligible. Patients with prior myeloablative transplant within the last 6 months are not eligible. A signed informed consent, assent form and HIPAA authorization are required.